Polymer excipients will better serve the pharma industry in its effort to develop robust, safe, and efficacious products to deliver drugs and increase bioavailability
During the recent American Association of Pharmaceutical Scientists (AAPS) annual meeting and exposition in Orlando, Florida, Ashland had both posters and presentations that supported its new campaign, “Advancing Drug Delivery with Superior Polymer Chemistry” that promotes a scientific approach to select polymer excipients that will better serve the pharmaceutical industry in its effort to develop robust, safe, and efficacious products to deliver drugs and increase bioavailability.
“A holistic, science-based approach to excipient selection rather than a traditional empirical approach affords the pharma industry the ability to consider the impact of polymer excipients in key areas of drug development, including manufacturing, bioavailability and stability,” said Thomas Durig, Senior Director of pharmaceutical and nutrition specialities, research and development, Ashland Specialty Ingredients.
During a presentation entitled, “Reducing Formulation Risk with Science-based Excipient Selection,” Durig explained that rational selections of excipients require an understanding of structure-function and structure-property relationships of input material.
Ashland utilises structure-function models in its development laboratories to find or develop polymer excipients that serve to improve the manufacture and end-use functionality of specific drug products.
Experts in polymer design and characterisation, Ashland scientists have a fundamental understanding of the functional performance and physicochemical stability of both cellulosic-based and vinyl pyrrolidone-based excipient technologies. Research scientists, within Ashland’s laboratories, work to advance polymer excipient technologies to improve product performance while enhancing bioavailability.
EP News Bureau – Mumbai